The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center
Abstract
OBJECTIVE: To assess the efficacy and safety of rituximab in adults responding poorly to standard treatment for severe autoimmune thrombotic thrombocytopenic purpura. DESIGN: Open-label prospective study. Outcomes in the survivors were compared to those of 53 historical survivors who were given therapeutic plasma exchange alone or with vincristine. SETTING: Hospitals belonging to the Reference Network for Thrombotic Microangiopathies in France. PATIENTS: Twenty-two adults with either no response or a disease exacerbation when treated with intensive therapeutic plasma exchange. INTERVENTION: Add-on rituximab therapy, four infusions over 15 days. MEASUREMENTS AND MAIN RESULTS: One patient died despite two rituximab infusions. In the rituximab-treated patients, the time to a durable remission was significantly shortened (p = .03), although the plasma volume required to achieve a durable remission was not significantly different compared to the controls. Platelet count recovery occurred within 35 days in all 21 survivors, compared to only 78% of the historical controls (p < .02). Of the rituximab-treated patients, none had a relapse within the first year but three relapsed later on. In patients treated with rituximab, a rapid and profound peripheral B-cell depletion was produced, lasting for 9 months and correlating with higher a disintegrin and metalloproteinase with thrombospondin-13 activity and lower anti-a disintegrin and metalloproteinase with thrombospondin-13 antibody titers. These differences were no longer significant after 12 months. No severe side effects occurred. CONCLUSIONS: Adults with severe thrombocytopenic purpura who responded poorly to therapeutic plasma exchange and who were treated with rituximab had shorter overall treatment duration and reduced 1-yr relapses than historical controls.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura
Sadler, J. E. (2008) · Blood · doi:10.1182/blood-2008-02-078170 · Cited by 574
Rituximab: Expanding Role in Therapy for Lymphomas and Autoimmune Diseases
Rastetter, W., Molina, A., & White, C. A. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.104249 · Cited by 213
Cited by
Thrombotic thrombocytopenic purpura
Joly, B. S., Coppo, P., & Veyradier, A. (2017) · Blood · doi:10.1182/blood-2016-10-709857 · Cited by 716
Self-citationConnelly‐Smith, L., Alquist, C. R., Aqui, N. A., Hofmann, J. C., Klingel, R., Onwuemene, O. A., Patriquin, C. J., Pham, H. P., Sanchez, A. P., Schneiderman, J., et al. (2023) · Journal of Clinical Apheresis · doi:10.1002/jca.22043 · Cited by 684
KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS
Rovin, B. H., Ayoub, I. M., Chan, T. M., Liu, Z.-H., Mejía-Vilet, J. M., & Floege, J. (2024) · Kidney International · doi:10.1016/j.kint.2023.09.002 · Cited by 517
The European Hematology Association Roadmap for European Hematology Research: a consensus document
Engert, A., Balduini, C., Brand, A., Coiffier, B., Cordonnier, C., Dohner, H., de Wit, T. D., Eichinger, S., Fibbe, W., Green, T., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.136739 · Cited by 81
Metadata
- Authors
- Froissart, A., Buffet, M., Veyradier, A., Poullin, P., Provôt, F., Malot, S., Schwarzinger, M., Galicier, L., Vanhille, P., Vernant, J.-P., Bordessoule, D., Guidet, B., Azoulay, E., Mariotte, E., Rondeau, E., Mira, J.-P., Wynckel, A., Clabault, K., Choukroun, G., Presne, C., Pourrat, J., Hamidou, M., & Coppo, P.
- Venue
- Critical Care Medicine
- Published
- 2012-01
- Volume
- 40
- Issue
- 1
- Pages
- 104-111
- ISSN
- 0090-3493 (ISSN-L)
- OpenAlex
- W2028444448
- Cited by
- 291
- References
- 2
- FWCI
- 7.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. https://app.cochat.ai/papers/10.1097/ccm.0b013e31822e9d66
- The paper
- Froissart, A., Buffet, M., Veyradier, A., Poullin, P., Provôt, F., Malot, S., Schwarzinger, M., Galicier, L., Vanhille, P., Vernant, J.-P., Bordessoule, D., Guidet, B., Azoulay, E., Mariotte, E., Rondeau, E., Mira, J.-P., Wynckel, A., Clabault, K., Choukroun, G., . . . Coppo, P. (2012). Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Critical Care Medicine. https://doi.org/10.1097/ccm.0b013e31822e9d66
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
